As we all know, TKI-based drugs are highly effective for lung cancer patients with EGFR mutation, however, most of the patients are without mutation, so other targets need to be found to achieve more precise treatment. A new target has now been identified and, furthermore, new drugs for this target are entering phase 2/3 clinical studies. PF-02341066 (crizotinib, clozotinib) is a newly developed small molecule drug for the EML4-ALK target, and preliminary results were reported by a team of researchers at the 46th ASCO meeting in Chicago, USA, in 2010. The results showed that for lung cancer patients with the fusion gene EML4-ALK, treatment with PF-02341066 resulted in significant symptom relief, with the longest remission time having been 8 months. As a result, the U.S. FDA granted direct approval for the drug to proceed directly to phase 3 clinical studies.